56例颅内及椎管内透明细胞型脑膜瘤的临床特征、治疗与预后因素
回顾性分析北京天坛医院2006至2016年间收治的56例颅内及椎管内透明细胞型脑膜瘤,占同期该类肿瘤的约0.39%。患者平均年龄32.3岁,女性多见,全切35例、次全切21例,26例复发,中位无进展生存期48.0个月。多因素分析确认Simpson III和IV级切除是较短无进展生存期的独立危险因素。
要点
- 透明细胞型脑膜瘤约占颅内及椎管内脑膜瘤的0.39%,好发于年轻女性。
- 全切35例、次全切21例,26例复发,中位无进展生存期48.0个月。
- Simpson III和IV级切除是较短无进展生存期的独立危险因素。
核心结论
- 透明细胞型脑膜瘤是WHO II级脑膜瘤的罕见亚型,多见于年轻患者,女性好发,复发率高。
- 作者认为,在可能的情况下,全切除是首选且最合适的治疗。
- 作者建议,对于原发肿瘤患者,无论切除范围如何,初次手术后均应放疗;对于复发患者,二次手术联合放疗可能作为有效治疗。
研究设计与样本
- 回顾性分析2006至2016年间在北京天坛医院接受手术治疗的14310例颅内及椎管内脑膜瘤中的56例透明细胞型脑膜瘤。
- 随访时间为术后10至206个月。
主要发现
- 透明细胞型脑膜瘤约占所有颅内及椎管内脑膜瘤的0.39%。
- 患者平均年龄32.3岁,男性20例、女性36例。
- 全切除35例,次全切除21例。
- 26例患者出现肿瘤复发,中位无进展生存期为48.0个月。
- 1年、3年、5年无进展生存率分别为87.5%、59.8%、41.8%;1年、3年、5年总生存率分别为98.2%、91.3%、65.8%,中位总生存期未获得。
关键数值与推荐
- 单因素分析显示全肿瘤切除与较好预后显著相关。
- 多因素分析确认仅Simpson III和IV级切除是较短无进展生存期的独立危险因素。
- 放疗在全切除和次全切除后均轻度改善无进展生存期,但因样本量小和随访时间短,未见显著差异。
- 12例患者死于肿瘤复发。
临床怎么用
- 作者认为,在可能的情况下,全切除是透明细胞型脑膜瘤首选且最合适的治疗。
- 作者建议,对于原发肿瘤患者,无论切除范围如何,初次手术后均应放疗。
- 作者认为,对于复发患者,二次手术联合放疗可能作为有效治疗。
局限性
- 原文指出样本量小。
- 原文指出随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intracranial and intraspinal clear cell meningiomas (CCMs) are rarely reported because of their extremely low incidence, and the current understanding of CCM is poor. The purpose of this study was to analyze the incidence and the clinical, radiologic, pathologic, and prognostic features of intracranial and intraspinal CCMs. METHODS: Among 14,310 cases of intracranial and intraspinal meningiomas that were surgically treated between 2006 and 2016 at Beijing Tian Tan Hospital, 56 were chosen for analysis and retrospectively reviewed. To determine which parameters were associated with longer progression-free survival (PFS) and overall survival (OS), statistical analysis was performed. RESULTS: CCMs accounted for approximately 0.39% of all intracranial and intraspinal meningiomas. Patients with CCM had a mean age of 32.3 years and there was a female predilection (20 males and 36 females). Gross total resection was achieved in 35 cases, and subtotal resection was achieved in 21 cases. All patients were followed up for 10-206 months after surgery. Twenty-six patients experienced tumor recurrence, and the median PFS was 48.0 months. The 1-year, 3-year, and 5-year PFS was 87.5%, 59.8%, and 41.8%, respectively. Twelve patients died of tumor recurrence, and the median OS was not available. The 1-year, 3-year, and 5-year OS was 98.2%, 91.3%, and 65.8%, respectively. Univariate analysis showed that total tumor removal was significantly associated with a better prognosis. Multivariate analysis confirmed only Simpson grade III and IV resection as an independent risk factor for shorter PFS. Radiotherapy mildly improved PFS after both gross total resection and subtotal resection, showing no significant difference because of the small sample size and short follow-up duration. CONCLUSIONS: CCM is a rare subtype of World Health Organization grade II meningioma. CCM typically involves young patients and shows a female predilection and high recurrence rate. When possible, total resection is the primary and most suitable treatment for CCM. For patients with primary tumors, radiotherapy is recommended after the initial operation regardless of the extent of resection. For patients with disease recurrence, secondary surgery combined with radiotherapy might serve as an effective treatment.
引用
- Tao X, Dong J, Hou Z, et al. Clinical Features, Treatment, and Prognostic Factors of 56 Intracranial and Intraspinal Clear Cell Meningiomas. World Neurosurg. 2018. PMID: 29325940. doi:10.1016/j.wneu.2017.12.173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。